Le Lézard
Classified in: Health, Science and technology

Serine Threonine Protein Kinase Pim 1 - Pipeline Review, H2 2019 - ResearchAndMarkets.com


The "Serine Threonine Protein Kinase Pim 1 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Summary

According to the recently published report 'SerineThreonine Protein Kinase Pim 1 - Pipeline Review, H2 2019'; Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Proto-oncogene serine/threonine-protein kinase Pim-1 is an enzyme encoded by the PIM1 gene. It promotes cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression CDKN1B at both transcriptional and post-translational levels. It mediates survival signaling through phosphorylation of BAD which induces release of the anti-apoptotic protein Bcl-X (L)/BCL2L1. It phosphorylation of MAP3K5, another proapoptotic protein by PIM1 significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis

The report 'SerineThreonine Protein Kinase Pim 1 - Pipeline Review, H2 2019' outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Scope

Reasons to buy

Key Topics Covered:

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/h5dhx3


These press releases may also interest you

at 21:45
Shop TJC Ltd. (TJC) is thrilled to announce the successful completion of its third collaboration with the iconic BBC...

at 21:32
Arctech has recently signed a contract for the 500MW Manah I power plant project in Oman, following its successful bid for the 588MW Manah II PV project in Oman earlier in 2023. This consecutive project win showcases Arctech's customized solutions...

at 21:15
Techtouch, Inc. (Headquarter: Tokyo, Japan, President/CEO: Naka Imuta) announced today that it ranked 8th in the 21st Technology Fast 50 Japan, with three-year revenue growth of 468.6%. Technology Fast 50 Japan, held annually by Deloitte Tohmatsu...

at 21:00
OKX Ventures, the investment arm of leading crypto exchange and Web3 technology company OKX, today published a report titled 'Unlocking the Infinite Potential of Crypto and AI.' The report explores the convergence of AI and crypto, a major trend in...

at 21:00
The "Strategic Storytelling for Internal Communications: Using the Power of Storytelling to Engage Employees, Manage Organizational Change, and Shape Workplace Cultures" conference has been added to  ResearchAndMarkets.com's offering. The Best...

at 20:50
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was...



News published on and distributed by: